| Bioactivity | RdRP-IN-9 (Compound 6b) is a reversible covalent allosteric inhibitor of RdRp. RdRP-IN-9 demonstrates high anti-coronavirus activity, with an EC50 value of 0.68 μM against HCoV-OC43 RdRP-IN-9 exerts a more prolonged antiviral effect by reversibly acylating Cys12 in the NiRAN domain of non-structural protein 12 (nsp 12) and exhibits synergistic anti-coronavirus activity with Molnupiravir (HY-135853) [1]. |
| Target | EC50: 0.68 μM (HCoV-OC43). |
| CAS | 1101848-34-3 |
| Formula | C19H21NO5 |
| Molar Mass | 343.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mei Y, et al. Lycorine esters exert anti-HCoV-OC43 effect through reversibly acylating cysteine residue in the nsp 12 NiRAN domain[J]. Bioorganic Chemistry, 2024: 108086. |
RdRP-IN-9
CAS: 1101848-34-3 F: C19H21NO5 W: 343.37
RdRP-IN-9 (Compound 6b) is a reversible covalent allosteric inhibitor of RdRp. RdRP-IN-9 demonstrates high anti-coronavi
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.